EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers

Xun Dong, Yaoyao Qu, Tongtong Sheng, Yuanming Fan, Silu Chen, Qinbo Yuan, Gaoxiang Ma, Yuqiu Ge

Aging · 2024

DOI: 10.18632/aging.205779 ↗

At a glance

Übersichtsarbeit in Aging, 2024. Written by Xun Dong and 7 co-authors. Institution: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China. Major MEDLINE topics: Neoplasms, Biomarkers, Tumor, Metabolomics, Body Fluids. Cited 1 times so far (Crossref); 76 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Metabolomics is a rapidly expanding field in systems biology used to measure alterations of metabolites and identify metabolic biomarkers in response to disease processes. The discovery of metabolic biomarkers can improve early diagnosis, prognostic prediction, and therapeutic intervention for cancers. However, there are currently no databases that provide a comprehensive evaluation of the relationship between metabolites and cancer processes. In this review, we summarize reported metabolites in body fluids across pan-cancers and characterize their clinical applications in liquid biopsy. We conducted a search for metabolic biomarkers using the keywords ("metabolomics" OR "metabolite") AND "cancer" in PubMed. Of the 22,254 articles retrieved, 792 were deemed potentially relevant for further review. Ultimately, we included data from 573,300 samples and 17,083 metabolic biomarkers. We collected information on cancer types, sample size, the human metabolome database (HMDB) ID, metabolic pathway, area under the curve (AUC), sensitivity and specificity of metabolites, sample source, detection method, and clinical features were collected. Finally, we developed a user-friendly online database, the Human Cancer Metabolic Markers Database (HCMMD), which allows users to query, browse, and download metabolite information. In conclusion, HCMMD provides an important resource to assist researchers in reviewing metabolic biomarkers for diagnosis and progression of cancers.

Subjects

MeSH terms (MEDLINE)

NeoplasmsBiomarkers, TumorMetabolomicsBody FluidsHumansLiquid BiopsyDatabases, FactualMetabolome

Author keywords

cancerdatabasediagnostic biomarkerliquid biopsymetabolites

Substances

Biomarkers, Tumor

Authors and institutions

  • State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
  • School of Public Health, Nanjing Medical University, Nanjing, China.
  • Department of Urology, Wuxi Fifth People’s Hospital, Wuxi, China.
  • The Clinical Metabolomics Center, China Pharmaceutical University, Nanjing, China.
  • Deparment of Oncology, Pukou Hospital of Chinese Medicine affiliated to China Pharmaceutical University, Nanjing, China.
  • Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, China.

Cite

APA

Dong, X., Qu, Y., Sheng, T., Fan, Y., Chen, S., Yuan, Q., Ma, G., & Ge, Y. (2024). HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers. Aging. https://doi.org/10.18632/aging.205779

Vancouver

Dong X, Qu Y, Sheng T, Fan Y, Chen S, Yuan Q, et al. HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers. Aging. 2024. doi:10.18632/aging.205779

BibTeX
@article{Dong2024,
  author = {Dong, Xun and Qu, Yaoyao and Sheng, Tongtong and Fan, Yuanming and Chen, Silu and Yuan, Qinbo and Ma, Gaoxiang and Ge, Yuqiu},
  title = {HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.205779}
}
Start for free →